In May 2025, a French pet medical research institute announced a significant advancement in feline heart disease treatment: a novel drug proven through clinical trials to effectively improve cardiac function, alleviate symptoms, and enhance quality of life and lifespan in cats.
The breakthrough has garnered international attention in the veterinary medical community.Developed over five years, the drug targets key molecular pathways involved in feline heart disease, such as myocardial remodeling and inflammation. In trials involving 200 cats with conditions like hypertrophic cardiomyopathy (HCM), the most common heart disease in felines, treated animals showed a 35% improvement in heart ejection fraction and reduced reliance on emergency veterinary visits compared to control groups. Side effects were minimal, with occasional mild gastrointestinal symptoms noted in 5% of cases.
“This is a game-changer for cats and their owners,” said lead researcher Dr. Sophie Leblanc. “For decades, treatment options for feline heart disease have been limited. This drug not only extends survival but also improves daily comfort, allowing cats to engage in normal activities like playing and climbing.”
The drug, which will be marketed under the name CardioFeline™, is set for commercial release in Europe by late 2025, with regulatory submissions underway in the U.S. and Japan. Veterinarians emphasize that while the medication is not a cure, it represents a critical step toward managing chronic heart conditions in cats, which affect an estimated 10% of senior felines worldwide.
“This achievement highlights the importance of investing in species-specific medical research,” said Dr. Alain Moreau of the European Society of Veterinary Cardiology. “Cats have unique physiological needs, and therapies tailored to them can make a profound difference.”
Related Topic:
